Pfizer (PFE) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Pfizer Revenue Highlights

Latest Revenue (Y)

$63.63B

Latest Revenue (Q)

$14.65B

Main Segment (Y)

Biopharma Segment

Main Geography (Y)

UNITED STATES

Pfizer Revenue by Period

Pfizer Revenue by Year

Date	Revenue	Change
2024-12-31	$63.63B	8.77%
2023-12-31	$58.50B	-41.70%
2022-12-31	$100.33B	23.43%
2021-12-31	$81.29B	93.97%
2020-12-31	$41.91B	-19.02%
2019-12-31	$51.75B	-3.54%
2018-12-31	$53.65B	2.10%
2017-12-31	$52.55B	-0.53%
2016-12-31	$52.82B	8.13%
2015-12-31	$48.85B	-1.52%
2014-12-31	$49.60B	-3.84%
2013-12-31	$51.58B	-12.55%
2012-12-31	$58.99B	-12.52%
2011-12-31	$67.42B	-0.57%
2010-12-31	$67.81B	35.59%
2009-12-31	$50.01B	3.55%
2008-12-31	$48.30B	-0.25%
2007-12-31	$48.42B	0.10%
2006-12-31	$48.37B	-5.71%
2005-12-31	$51.30B	-2.32%
2004-12-31	$52.52B	16.22%
2003-12-31	$45.19B	39.59%
2002-12-31	$32.37B	0.35%
2001-12-31	$32.26B	9.08%
2000-12-31	$29.57B	82.51%
1999-12-31	$16.20B	19.64%
1998-12-31	$13.54B	8.32%
1997-12-31	$12.50B	10.60%
1996-12-31	$11.31B	12.82%
1995-12-31	$10.02B	21.01%
1994-12-31	$8.28B	10.75%
1993-12-31	$7.48B	-

Pfizer generated $63.63B in revenue during NA 2024, up 8.77% compared to the previous quarter, and up 122.95% compared to the same period a year ago.

Pfizer Revenue by Quarter

Date	Revenue	Change
2025-06-29	$14.65B	6.84%
2025-03-29	$13.71B	-22.79%
2024-12-31	$17.76B	0.34%
2024-09-29	$17.70B	33.27%
2024-06-30	$13.28B	-10.73%
2024-03-31	$14.88B	4.42%
2023-12-31	$14.25B	7.69%
2023-10-01	$13.23B	3.91%
2023-07-02	$12.73B	-30.35%
2023-04-02	$18.28B	-24.73%
2022-12-31	$24.29B	7.30%
2022-10-02	$22.64B	-18.40%
2022-07-03	$27.74B	8.11%
2022-04-03	$25.66B	7.65%
2021-12-31	$23.84B	-1.06%
2021-10-03	$24.09B	26.96%
2021-07-04	$18.98B	30.14%
2021-04-04	$14.58B	24.80%
2020-12-31	$11.68B	-3.68%
2020-09-27	$12.13B	2.80%
2020-06-28	$11.80B	-1.89%
2020-03-29	$12.03B	-5.20%
2019-12-31	$12.69B	0.06%
2019-09-29	$12.68B	-4.40%
2019-06-30	$13.26B	1.11%
2019-03-31	$13.12B	-6.14%
2018-12-31	$13.98B	5.10%
2018-09-30	$13.30B	-1.25%
2018-07-01	$13.47B	4.34%
2018-04-01	$12.91B	-5.82%
2017-12-31	$13.70B	4.06%
2017-10-01	$13.17B	2.11%
2017-07-02	$12.90B	0.92%
2017-04-02	$12.78B	-6.22%
2016-12-31	$13.63B	4.46%
2016-10-02	$13.04B	-0.78%
2016-07-03	$13.15B	1.09%
2016-04-03	$13.01B	-7.42%
2015-12-31	$14.05B	16.22%
2015-09-27	$12.09B	1.97%
2015-06-28	$11.85B	9.10%
2015-03-29	$10.86B	-17.18%
2014-12-31	$13.12B	6.12%
2014-09-28	$12.36B	-3.23%
2014-06-29	$12.77B	12.51%
2014-03-30	$11.35B	-16.26%
2013-12-31	$13.56B	7.24%
2013-09-29	$12.64B	-2.54%
2013-06-30	$12.97B	-3.90%
2013-03-31	$13.50B	-10.41%
2012-12-31	$15.07B	7.81%
2012-09-30	$13.98B	0.06%
2012-07-01	$13.97B	0.89%
2012-04-01	$13.85B	-17.32%
2011-12-31	$16.75B	0.82%
2011-10-02	$16.61B	0.75%
2011-07-03	$16.48B	2.88%
2011-04-03	$16.02B	-8.75%
2010-12-31	$17.56B	9.79%
2010-10-03	$15.99B	-6.64%
2010-07-04	$17.13B	3.35%
2010-04-04	$16.58B	0.24%
2009-12-31	$16.54B	42.30%
2009-09-27	$11.62B	5.80%
2009-06-28	$10.98B	1.08%
2009-03-29	$10.87B	-11.98%
2008-12-31	$12.35B	3.12%
2008-09-28	$11.97B	-1.29%
2008-06-29	$12.13B	2.37%
2008-03-30	$11.85B	-7.94%
2007-12-31	$12.87B	-

Pfizer generated $14.65B in revenue during Q2 2025, up 6.84% compared to the previous quarter, and up 98.48% compared to the same period a year ago.

Pfizer Revenue Breakdown

Pfizer Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Biopharma Segment	$8.39B	$7.58B	$98.99B	-	-
Total Alliance Biopharmaceuticals	-	-	$8.54B	$7.65B	$5.42B
Comirnaty	-	-	$3.10B	-	-
Total Sterile Injectable Pharmaceuticals	-	-	-	$5.75B	$5.32B
Total Biosimilars	-	-	-	$2.34B	$1.53B

Pfizer's latest annual revenue breakdown by segment (product or service), as of Dec 24: Biopharma Segment (100.00%).

Quarterly Revenue by Product

Product/Service	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Oct 23	Jul 23	Apr 23	Dec 22	Oct 22	Jul 22	Apr 22	Dec 21	Oct 21	Jul 21	Apr 21	Sep 20	Jun 20	Mar 20
Biopharma Segment	$14.30B	$17.41B	$17.39B	$2.07B	$2.17B	$13.87B	$12.93B	$1.72B	$1.25B	$1.61B	-	-	-	-	-	-	-	-	-	-
Comirnaty	-	-	-	-	-	-	$140.00M	$300.00M	$1.70B	$600.00M	$68.00M	$800.00M	-	-	-	-	-	-	-	-
Total Alliance Biopharmaceuticals	-	-	-	-	-	-	-	$1.97B	$1.69B	$2.32B	$2.31B	$1.93B	$2.07B	$1.88B	$1.77B	-	-	-	-	-
Total Sterile Injectable Pharmaceuticals	-	-	-	-	-	-	-	-	-	-	-	$1.29B	$1.33B	$1.44B	$1.44B	$1.38B	$1.48B	-	-	-
Total Biosimilars	-	-	-	-	-	-	-	-	-	-	-	$580.00M	$605.00M	$680.00M	$575.00M	$559.00M	$530.00M	-	-	-
Biopharma, Upjohn And Consumer Healthcare Segments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$12.13B	$11.80B	$12.03B
Upjohn Segment	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$76.00M	$79.00M	$78.00M

Pfizer's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Biopharma Segment (100.00%).

Pfizer Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 24	Dec 23	Dec 22	Dec 21	Dec 20
Emerging Markets	$8.88B	$12.00B	$20.10B	-	-
Developed Rest Of World	$16.06B	$7.76B	$15.78B	-	-
UNITED STATES	$38.69B	$27.09B	$42.47B	$29.75B	$21.71B
Developed Europe	-	$11.65B	$21.98B	-	-

Pfizer's latest annual revenue breakdown by geography, as of Dec 24: UNITED STATES (60.81%), Developed Rest Of World (25.24%), and Emerging Markets (13.95%).

Quarterly Revenue by Country

Country	Jun 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Oct 23	Jul 23	Apr 23	Oct 22	Jul 22	Apr 22	Dec 21	Oct 21	Jul 21	Apr 21	Dec 20	Sep 20	Jun 20	Mar 20
UNITED STATES	$8.89B	$9.22B	$12.06B	$7.89B	$9.51B	$4.59B	$7.80B	$6.18B	$8.51B	$13.85B	$11.22B	$8.92B	$7.48B	$7.08B	$7.59B	$7.60B	$4.94B	$5.72B	$5.40B	$5.65B
Developed Rest Of World	$3.39B	$6.28B	$3.41B	$3.16B	$3.20B	$2.91B	$1.07B	-	-	-	-	-	-	-	-	-	-	-	-	-
Emerging Markets	$2.37B	$2.26B	$2.23B	$2.23B	$2.17B	$2.31B	$2.37B	-	-	-	-	-	-	-	-	-	-	-	-	-
Developed Europe	-	-	-	-	-	$4.43B	$1.98B	-	-	-	-	-	-	-	-	-	-	-	-	-

Pfizer's latest quarterly revenue breakdown by geography, as of Jun 25: UNITED STATES (60.70%), Developed Rest Of World (23.16%), and Emerging Markets (16.15%).

Pfizer Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
MRK	Merck	$64.17B	$15.81B
PFE	Pfizer	$63.63B	$14.65B
BMY	Bristol-Myers Squibb	$48.30B	$12.27B
SNY	Sanofi	$43.07B	$11.12B
AMGN	Amgen	$33.42B	$9.18B
GSK	GSK	$30.33B	$7.36B
GILD	Gilead Sciences	$28.75B	$6.67B
DHR	Danaher	$23.88B	$6.05B
SYK	Stryker	$22.59B	$6.02B
BSX	Boston Scientific	$16.75B	$5.06B

PFE Revenue FAQ

What is Pfizer’s yearly revenue?

Pfizer's yearly revenue for 2024 was $63.63B, representing an increase of 8.77% compared to 2023. The company's yearly revenue for 2023 was $58.5B, representing a decrease of -41.70% compared to 2022. PFE's yearly revenue for 2022 was $100.33B, representing an increase of 23.43% compared to 2021.

What is Pfizer’s quarterly revenue?

Pfizer's quarterly revenue for Q2 2025 was $14.65B, a 6.84% increase from the previous quarter (Q1 2025), and a 10.31% increase year-over-year (Q2 2024). The company's quarterly revenue for Q1 2025 was $13.72B, a -22.79% decrease from the previous quarter (Q4 2024), and a -7.82% decrease year-over-year (Q1 2024). PFE's quarterly revenue for Q4 2024 was $17.76B, a 0.34% increase from the previous quarter (Q3 2024), and a 24.66% increase year-over-year (Q4 2023).

What is Pfizer’s revenue growth rate?

Pfizer's revenue growth rate for the last 3 years (2022-2024) was -36.58%, and for the last 5 years (2020-2024) was 51.83%.

What are Pfizer’s revenue streams?

Pfizer's revenue streams in c 24 are Biopharma Segment

What is Pfizer’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Pfizer was Biopharma Segment. This segment made a revenue of $8.39B, representing 100.00% of the company's total revenue.